Thymoquinone upregulates miR‐125a‐5p, attenuates STAT3 activation, and potentiates doxorubicin antitumor activity in murine solid Ehrlich carcinoma

2021 ◽  
Author(s):  
Hebatallah H. Atteia ◽  
Manar H. Arafa ◽  
Nanies S. Mohammad ◽  
Dalia M. Amin ◽  
Amr T. Sakr
Keyword(s):  
Antitumor Activity ◽  
Ehrlich Carcinoma ◽  
Solid Ehrlich Carcinoma

ANTITUMOR EFFECT OF COLLOIDAL SILVER BISILICATE IN EXPERIMENTAL IN VITRO AND IN VIVO STUDIES

2019 ◽  
Vol 65 (5) ◽  
pp. 760-765
Author(s):  
Margarita Tyndyk ◽  
Irina Popovich ◽  
A. Malek ◽  
R. Samsonov ◽  
N. Germanov ◽  
...  
Keyword(s):  
Antitumor Activity ◽  
Tumor Growth ◽  
Tumor Cells ◽  
Human Tumor ◽  
Significant Inhibition ◽  
In Vivo Studies ◽  
Ehrlich Carcinoma ◽  
In Vivo Experiments

The paper presents the results of the research on the antitumor activity of a new drug - atomic clusters of silver (ACS), the colloidal solution of nanostructured silver bisilicate Ag6Si2O7 with particles size of 1-2 nm in deionized water. In vitro studies to evaluate the effect of various ACS concentrations in human tumor cells cultures (breast cancer, colon carcinoma and prostate cancer) were conducted. The highest antitumor activity of ACS was observed in dilutions from 2.7 mg/l to 5.1 mg/l, resulting in the death of tumor cells in all studied cell cultures. In vivo experiments on transplanted Ehrlich carcinoma model in mice consuming 0.75 mg/kg ACS with drinking water revealed significant inhibition of tumor growth since the 14th day of experiment (maximally by 52% on the 28th day, p < 0.05) in comparison with control. Subcutaneous injections of 2.5 mg/kg ACS inhibited Ehrlich's tumor growth on the 7th and 10th days of the experiment (p < 0.05) as compared to control.

scholarly journals Polymeric nano-encapsulation of 5-fluorouracil enhances anti-cancer activity and ameliorates side effects in solid Ehrlich Carcinoma-bearing mice

2018 ◽  
Vol 105 ◽  
pp. 215-224 ◽  
Author(s):  
Yusuf A. Haggag ◽  
Mohamed A. Osman ◽  
Sanaa A. El-Gizawy ◽  
Ahmed E. Goda ◽  
Maha M. Shamloula ◽  
...  
Keyword(s):  
Side Effects ◽  
Ehrlich Carcinoma ◽  
Anti Cancer ◽  
Cancer Activity ◽  
Solid Ehrlich Carcinoma

scholarly journals ACONITINE-CONTAINING AGENT ENHANCES ANTITUMOR ACTIVITY OF DICHLOROACETATE AGAINST EHRLICH CARCINOMA

2015 ◽  
Vol 37 (3) ◽  
pp. 192-196 ◽  
Author(s):  
O N Pyaskovskaya ◽  
I V Boychuk ◽  
A G Fedorchuk ◽  
D L Kolesnik ◽  
O I Dasyukevich ◽  
...  
Keyword(s):  
Antitumor Activity ◽  
Total Dose ◽  
Lactate Level ◽  
Phagocytic Activity ◽  
Tumor Tissue ◽  
Antitumor Action ◽  
Ehrlich Carcinoma ◽  
Ros Production ◽  
Antiangiogenic Agent ◽  
Ldh Activity

Significant variability of anticancer efficacy of dichloroacetate (DCA) stimulated an active search for the agents capable to enhance it antitumor action. Therefore, the aim of this work is the study of capability of aconitine-containing antiangiogenic agent BC1 to enhance anticancer activity of DCA against Ehrlich carcinoma. Materials and Methods: DCA (total dose was 1.3 g/kg of b.w.) and BC1 (total dose was 0.9 mg/kg of b.w.) were administered per os starting from the 2nd and 3rd days, respectively (8 admini strations for each agent). Antitumor efficacy of agents was estimated. Lactate level, LDH activity and the state of mitochondrial electron transport chain in tumor cells as well as phagocytic activity and reactive oxygen species (ROS) production of tumor-associated macrophages (TAM) were studied. Results: Combined administration of DCA and ВС1 resulted in 89.8% tumor growth inhibition (p < 0.001), what is by 22.5% (p < 0.05) higher that that of DCA alone. This combined treatment was accompanied with a decrease of lactate level in tumor tissue by 30% (p < 0.05) and significant elevation of LDH activity by 70% (p < 0.01). Increased level of NO-Fe-S clusters and 2-fold reduction of Fe-S cluster content were revealed in tumor tissue of mice after DCA and BC1 administration. It was shown that combined therapy did not effect TAM quantity and their phagocytic activity but stimulated ROS production by TAMs by 78% (p < 0.05) compared to this index in control animals. Conclusion: Antiangiogenic agent ВС1 in combination with DCA considerably enhances antitumor activity of DCA via significant decrease of Fe-S-containing protein level resulted from substantial elevation of nitrosylation of these proteins.

scholarly journals Phytochemical profile, toxicological evaluation of Rhipsalis baccifera (Sol.) Stearn (Cactaceae) extract and their antitumor activity in Ehrlich carcinoma-bearing mice

2021 ◽  
Author(s):  
Jéssica Alves Cavalcantea ◽  
Luiz da Silva Maia Neto ◽  
Anna Lígia de Castro Figueiredo ◽  
Weslley Oliveira ◽  
José Roberto Pimentel Cabral de Seixas ◽  
...  
Keyword(s):  
Antitumor Activity ◽  
Therapeutic Potential ◽  
Lethal Dose ◽  
Artemia Salina ◽  
Subsequent Treatment ◽  
Ehrlich Carcinoma ◽  
Toxicological Evaluation ◽  
Phytochemical Profile

<i>Rhipsalis baccifera</i> (Sol.) Stearn is a typical cactus from tropical regions with wide geographic distribution, and its therapeutic potential is not yet fully understood, such as antitumoral property. Thus, this study evaluated the cytotoxic ethanolic extract of <i>R. baccifera</i> (EERB) and its antitumor activity against Erlich's tumor in mice. The EERB was obtained, and its phytochemical profile was filed by thin-layer chromatography. The toxicity was evaluated in vitro and in vivo using the microcrustacean<i> Artemia salina</i> Leach and mice. The lethal dose was determined after implantation of a tumor cell suspension, with subsequent treatment with EERB (200 mg/kg and 100 mg/kg) 48h after implantation. These values represent the tenth part of the DL<sub>50</sub> and CL<sub>50</sub>, respectively. The presence of phenols, tannins and triterpenes were demonstrated in the phytochemical results. Toxicity was dose-dependent, and the tumor inhibition was 84.1% and 75.8% at doses of 200 mg/kg and 100 mg/kg, respectively. We can highlight that the growth of Erlich's carcinoma suffered inhibitory effects against the EERB. EERB was found to have low acute toxicity and a high potential for use in antitumor therapy. Thus, new studies involving pre-clinical and clinical analyses of the extract are essential to determine the safe dose.

STUDIES ON THE IN VITRO ANTITUMOR ACTIVITY OF FATTY ACIDS: II. SATURATED DICARBOXYLIC ACIDS

1960 ◽  
Vol 38 (6) ◽  
pp. 597-603 ◽  
Author(s):  
Joseph F. Morgan ◽  
Susan Tolnai ◽  
Gordon F. Townsend
Keyword(s):  
Fatty Acids ◽  
Antitumor Activity ◽  
Royal Jelly ◽  
Dicarboxylic Acids ◽  
Ehrlich Carcinoma ◽  
Decenoic Acid ◽  
Fatty Acid Chain ◽  
Transplantable Leukemia ◽  
Akr Mice

Previous studies, which showed that 10-hydroxy-2-decenoic acid from royal jelly possessed in vitro antitumor activity, have been extended to saturated dicarboxylic fatty acids. Seven of eight compounds tested in a series of chain length from C3 to C10 completely prevented the development of the ascites forms of the 6C3HED lymphosarcoma, the Ehrlich carcinoma, and the TA3 mammary carcinoma, as well as the transplantable leukemia of AKR mice. This in vitro antitumor activity could be demonstrated only at pH values below 5.0 and required admixture of the tumor cells and test compounds prior to inoculation of the mice. In general, the antitumor activity of the saturated dicarboxylic acids was found to increase progressively with increasing length of the fatty acid chain.

THE EFFECTS OF THE COMBINATION OF RAPAMYCIN WITH DOXORUBICIN AND PACLITAXEL ON THE MODELS OF TRANSPLANTABLE TUMORS IN MICE

2019 ◽  
Vol 65 (4) ◽  
pp. 614-622
Author(s):  
Mariya Yurova ◽  
Margarita Tyndyk ◽  
Yekaterina Gubareva ◽  
Yelena Fedoros ◽  
Viktor Anisimov
Keyword(s):  
Antitumor Activity ◽  
Protective Effect ◽  
Total Dose ◽  
Mtor Inhibitor ◽  
Combined Treatment ◽  
Mammary Adenocarcinoma ◽  
Ehrlich Carcinoma ◽  
Tumor Growth Inhibition ◽  
Chemotherapeutic Drugs ◽  
Transplantable Tumors

The study aimed to assess combined treatment with mTOR inhibitor rapamycin and cytotoxic drugs (doxorubicin and paclitaxel) on two models of transplantable tumors - mammary adenocarcinoma in male HER-2/neu transgenic FVB/N mice and solid Ehrlich carcinoma in male 129/Sv mice. Rapamycin (total dose of 3.6 mg kg), doxorubicin (total dose of 15 mg/ kg), paclitaxel (total dose of 6 mg/kg) or their combination were intraperitoneally injected to mice with developed tumor node. Rapamycin showed its own antitumor activity by tumor growth inhibition up to 42% in mammary adenocarcinoma model and up to 57% in Ehrlich carcinoma model. A tendency to an increase in the antitumor activity of chemotherapeutic drugs with the addition of rapamycin was revealed. The cyto-protective effect of the mTOR inhibitor was observed during therapy with doxorubicin and paclitaxel, expressed in a significant decrease in the level of apoptosis in normal epithelium of jejunum crypts. Thus, revealed protective effect of mTOR inhibitor on jejunum epithelium could be applied for reduction of chemotherapeutic drugs enterotoxic effect without any efficiency reduction. Thus, in perspective that could expand the possibilities of standard chemotherapeutic treatment and improve the quality of life of cancer patients.

Sign in / Sign up

Export Citation Format

Share Document